<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011665'>Takotsubo cardiomyopathy</z:hpo> is an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> syndrome characterized by myocardial hypocontractility from the mid left ventricle to the apex </plain></SENT>
<SENT sid="1" pm="."><plain>It is precipitated by extreme stress and can be triggered by intravenous <z:chebi fb="2" ids="33567">catecholamine</z:chebi> administration, particularly <z:chebi fb="2" ids="28918">epinephrine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Despite its grave presentation, <z:hpo ids='HP_0011665'>Takotsubo cardiomyopathy</z:hpo> is rapidly reversible, with generally good prognosis </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesized that this represents switching of <z:chebi fb="2" ids="28918">epinephrine</z:chebi> signaling through the pleiotropic β(2)-adrenergic receptor (β(2)AR) from canonical stimulatory G-protein-activated cardiostimulant to inhibitory G-protein-activated cardiodepressant pathways </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: We describe an in vivo rat model in which a high intravenous <z:chebi fb="2" ids="28918">epinephrine</z:chebi>, but not <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi>, bolus produces the characteristic reversible apical <z:hpo ids='HP_0000716'>depression</z:hpo> of myocardial contraction coupled with basal hypercontractility </plain></SENT>
<SENT sid="5" pm="."><plain>The effect is prevented via G(i) inactivation by <z:e sem="disease" ids="C0043167" disease_type="Disease or Syndrome" abbrv="">pertussis</z:e> toxin pretreatment. β(2)AR number and functional responses were greater in isolated apical cardiomyocytes than in basal cardiomyocytes, which confirmed the higher apical sensitivity and response to circulating <z:chebi fb="2" ids="28918">epinephrine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro studies demonstrated high-dose <z:chebi fb="2" ids="28918">epinephrine</z:chebi> can induce direct cardiomyocyte cardiodepression and cardioprotection in a β(2)AR-Gi-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain>Preventing <z:chebi fb="2" ids="28918">epinephrine</z:chebi>-G(i) effects increased mortality in the Takotsubo model, whereas β-blockers that activate β(2)AR-G(i) exacerbated the <z:chebi fb="2" ids="28918">epinephrine</z:chebi>-dependent negative inotropic effects without further <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, <z:chebi fb="0" ids="50567">levosimendan</z:chebi> rescued the <z:hpo ids='HP_0011009'>acute</z:hpo> cardiac dysfunction without increased mortality </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We suggest that biased agonism of <z:chebi fb="2" ids="28918">epinephrine</z:chebi> for β(2)AR-G(s) at low concentrations and for G(i) at high concentrations underpins the <z:hpo ids='HP_0011009'>acute</z:hpo> apical cardiodepression observed in <z:hpo ids='HP_0011665'>Takotsubo cardiomyopathy</z:hpo>, with an apical-basal gradient in β(2)ARs explaining the differential regional responses </plain></SENT>
<SENT sid="10" pm="."><plain>We suggest this <z:chebi fb="2" ids="28918">epinephrine</z:chebi>-specific β(2)AR-G(i) signaling may have evolved as a cardioprotective strategy to limit <z:chebi fb="2" ids="33567">catecholamine</z:chebi>-induced myocardial toxicity during <z:hpo ids='HP_0011009'>acute</z:hpo> stress </plain></SENT>
</text></document>